Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- QTM +20.1%
- ALQA +14.3%, (also to acquire the business of Soluble Systems)
- ZUMZ +10.8%, (Zumiez reports September same store sales +6.3% vs -1.8% September last year and -1.5% last month; raising Q3 EPS and sales guidance above consensus)
- DLGNF +4.3%
M&A news:
- PHMD +47% (PhotoMedex to sell its consumer products business to ICTV Brands for $9.5 mln)
- CRM +2.5% (likely to be remainer co interested in offer for TWTR)
Other news:
- JAGX +31% (signs a non-binding LOI with Napo Pharma to potentially merge the 2 companies; Aspire Capital Fund purchases 348,601 shares of Jaguar common stock at $2.28/share)
- AUPH +23.7% (announces 24-week data in all 10 patients from the AURION study)
- SCYX +14.4% (announces complete results from two phase 2 Studies of Oral SCY-078 in patients with candida spp. infections; study results confirm overall antifungal activity of oral SCY-078 in patients with candida infections)
- CATB +7% (presents data from Part A of the MoveDMD trial of edasalonexent for the treatment of DMD)
- HIMX +3.7% (higher on Dialog Semi upside sales guidance)
- RDHL +3.7% (provides progress update on RHB-104 phase III Crohn's disease program and introduces option for early stop for success in Q2/2017)
- MET +3.3% ( confirms that Brighthouse Financial filed a Registration Statement on Form 10 with the SEC)
- LRCX +3.2% (higher on Dialog Semi upside sales guidance)
- CHK +2.2% (recent transactions significantly improve capital structure)
- JD +1.9% (Wal-Mart increases passive stake)
Analyst comments:
- YGE +4.9% (upgraded to Buy from Hold at Axiom Capital)
- JASO +3.9% (upgraded to Buy from Hold at Axiom Capital)
- BGFV +3.5% (upgraded to Buy from Hold at Deutsche Bank)
- CPTA +2.1% (upgraded to Buy from Neutral at Ladenburg Thalmann)